Overweight status Linked to Poorer outcomes in Multiple Myeloma Patients Receiving CAR T-Cell Therapy
A new study reveals that multiple myeloma patients with an overweight BMI experience significantly worse outcomes following anti-BCMA CAR T-cell therapy compared to those with normal weight or obesity,highlighting the critical role of metabolic factors in treatment efficacy.
A retrospective analysis of 134 patients with multiple myeloma (MM) undergoing chimeric antigen receptor T-cell (CAR T) therapy has uncovered a surprising correlation: an overweight body mass index (BMI) appears to negate the potential benefits often seen in patients with obesity, leading to poorer outcomes.
The study cohort was diverse in terms of the specific CAR T-cell product received: 51.5% received idecabtagene vicleucel (ide-cel; Abecma), 23.9% received ciltacabtagene autoleucel (cilta-cel; Carvykti),and 24.6% received an investigational therapy. The median BMI of the group was 26.7 kg/m2, with patients categorized as normal weight (BMI < 25 kg/m2), overweight (25-29.9 kg/m2), or obese (≥30.0 kg/m2), representing 36.6%, 32.8%, and 30.6% of the cohort, respectively.
A “U-Shaped” Relationship emerges
Researchers observed a distinct “U-shaped” association between BMI and treatment outcomes. Patients classified as overweight demonstrated numerically worse 12-month progression-free survival (PFS) – 28.8% – compared to those with normal weight (51.9%) and those with obesity (62.6%; P < .001). This pattern extended to 12-month overall survival (OS),with rates of 61.4%, 82.9%, and 84.2% for the overweight, normal weight, and obese groups, respectively (P = .006). Complete response rates also followed this trend: 36.4% in the overweight group versus 42.9% and 56.1% in the normal weight and obese groups (P = .185).
Further analysis using Cox regression revealed that overweight status was significantly associated with a higher risk of disease progression (HR, 2.35; 95% CI, 1.5-3.67; P < .001) and death (HR, 2.38; 95% CI, 1.32-4.28; P = .004) compared to patients with normal weight or obesity. Importantly, these associations remained significant even after adjusting for other relevant factors, with adjusted hazard ratios of 1.69 (P = .038) for PFS and 2.33 (P =.031) for OS.
The “Immunometabolic Valley”
The findings support the authors’ hypothesis that overweight individuals may lack the beneficial biological characteristics observed in both normal-weight and obese patients.”we hypothesized that normal-weight patients have more favorable tumor biology, whereas obesity may paradoxically confer enhanced immunotherapy sensitivity and CAR T-cell therapy efficacy, as seen in other cancers,” one author explained. The researchers propose that the overweight state represents a unique “immunometabolic valley,” a phenotype lacking the advantages of either extreme, and therefore experiencing the poorest outcomes.
Future Research and Implications
Acknowledging the limitations of this single-center, observational study – including potential selection bias and the inherent imprecision of BMI as a measure of metabolic health – the authors emphasize the need for further inquiry. They suggest that future studies incorporate comprehensive body composition analysis to better capture the nuances of individual metabolic profiles.
“Further validation and mechanistic research are essential to elucidate the underlying biological processes,” the authors concluded. “This research could uncover novel therapeutic targets or modifiable factors to be leveraged to improve CAR T-cell therapy outcomes in MM.” This work highlights the growing recognition that host biology, and specifically metabolic status, plays a crucial role in the success of cancer immunotherapies, paving the way for more personalized and effective treatment strategies.
